Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022

- June 10th, 2019

Adverum Biotechnologies (NASDAQ:ADVM) has announced it has dosed the first patient in its second cohort of the ongoing OPTIC phase 1 clinical trial for ADVM-022 to treat wet age-related macular degeneration (wet AMD). As quoted in the press release: Patients are receiving a single intravitreal injection of gene therapy candidate ADVM-022 at a dose of … Continued

Adverum Biotechnologies (NASDAQ:ADVM) has announced it has dosed the first patient in its second cohort of the ongoing OPTIC phase 1 clinical trial for ADVM-022 to treat wet age-related macular degeneration (wet AMD).

As quoted in the press release:

Patients are receiving a single intravitreal injection of gene therapy candidate ADVM-022 at a dose of 2 x 10^11 vg/eye.

“We are pleased to report continued progress in the OPTIC trial by dosing the first patient in the second cohort,” said Aaron Osborne, MBBS MRCOphth, chief medical officer of Adverum. “We believe ADVM-022 has potential to provide sustained therapeutic benefit with a single intravitreal injection to patients living with wet AMD. In the first cohort of patients, we have seen a robust preliminary anatomical response and no serious adverse events to date. We look forward to completing recruitment of the second cohort in OPTIC, and to presenting the 24 week primary and secondary outcomes from the first cohort of patients at a scientific meeting in the second half of 2019.”

“ADVM-022 has the potential to transform the way we treat patients with neovascular AMD,” added Arshad M. Khanani, M.D, M.A, trial investigator and director of clinical research at Sierra Eye Associates. “In addition to greatly alleviating treatment burden, I believe that a more consistent treatment could  improve long-term vision outcomes for patients in clinical practice. We are excited to be participating in OPTIC.”

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply